Preliminary data on a new opioid risk assessment measure: The Brief Risk Interview


  • Ted Jones, PhD
  • Todd Moore, PhD



medication aberrant behavior, opioid risk assessment, opioid pain management, Brief Risk Interview


Risk assessment and stratification have become a central issue in prescribing opioids to patients with chronic pain. Research to date on various risk screening measures has shown that a clinical interview by an experienced clinician offers superior predictive ability in identifying patients who are more likely to engage in future medication aberrant behavior. The current study represents a pilot study of an interview rating scale that is designed to replicate this clinical assessment. This study compares the predictions of medication aberrant behavior made by the Opioid Risk Tool, the Screener and Opioid Assessment for Patients with Pain- Revised, and the new interview rating scale, the Brief Risk Interview (BRI). A sample of 196 patients was assessed by each of the three risk measures and then follow-up data were gathered at 6 months post interview to determine which patients had engaged in medication aberrant behavior and had been discharged from the practice. The BRI shows superior predictive ability in identifying patients who later engage in medication aberrant behavior. Although more study in other settings is needed, these preliminary data suggest that the Brief Risk Interview could be a useful tool for any pain clinician in assessing risk through the use of information gathered in a brief interview. Keywords: medication aberrant behavior, opioid risk assessment, opioid pain management, Brief Risk Interview DOI:10.5055/jom.2013.0143



Martin BI, Deyo RA, Mirza SK, et al.: Expenditures and health status among adults with back and neck problems. JAMA. 2008; 299: 656-664.

Joranson DE, Gilson AM, Dahl JL, et al.: Pain management, controlled substances, and state medical board policy: A decade of change. J Pain Symptom Manage. 2002; 23: 138-147.

Compton WM, Volkow ND: Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend. 2006; 81(2): 103-107.

Gourlay D, Heit HA, Almahrezi A: Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.

Passik SD, Kirsh KL, Casper D: Addiction-related assessment tools and pain management: Instruments for screening, treatment planning, and monitoring compliance. Pain Med. 2008; 9(2): S145-S166.

Bronstein K, Passik SP, Muntz L, et al.: Predicting abnormal urine drug testing in patients on chronic opioid therapy. Poster, PainWeek. September 8-11, 2010.

Moore TM, Jones T, Browder JH, et al.: A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009; 10(8): 1426-1433.

Jones T, Moore TM, Levy J, et al.: A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain. 2012; 28(2): 93-100.

Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med. 2005; 5(6): 432-442.

Butler SF, Fernandez K, Beloit C, et al.: Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain. 2008; 9(4): 360-372.

Jones T, Passik S: A comparison of methods in administering the opioid risk tool. J Opioid Manag. 2011; 7(5): 347-352.



How to Cite

Jones, PhD, T., and T. Moore, PhD. “Preliminary Data on a New Opioid Risk Assessment Measure: The Brief Risk Interview”. Journal of Opioid Management, vol. 9, no. 1, Jan. 2013, pp. 19-27, doi:10.5055/jom.2013.0143.